34945.jpg
ProQR to Present at Cowen Health Care Conference
March 05, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
34945.jpg
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
February 27, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
34945.jpg
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
January 29, 2019 08:30 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
34945.jpg
ProQR to Host R&D Day in New York on January 29
January 03, 2019 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at...
34945.jpg
ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
October 31, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
34945.jpg
ProQR to Present at the Chardan Genetic Medicines Conference
October 02, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
34945.jpg
ProQR Announces Presentations at the OTS Annual Meeting
September 24, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
34945.jpg
ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
June 28, 2018 07:00 ET | ProQR Therapeutics N.V.
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene. QR-313 is a...
34945.jpg
ProQR to Present at the JMP Life Sciences Conference
June 14, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, June 14, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
34945.jpg
ProQR Announces Results for the First Quarter of 2018
May 09, 2018 07:00 ET | ProQR Therapeutics N.V.
Key updates Eight out of twelve patients have been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with...